~~<i id='43325D101E'><strike id='43325D101E'><tt id='43325D101E'><pre id='43325D101E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：leisure time 2025-09-06 02:10:27 - browse：93341

Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

Read on for brief explanations of what we’re watching for from each company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Activists slam private health insurers over coverage restrictions

hotspot

explore

entertainment

Wikipedia

focus

entertainment

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hepatitis C has a cure — but many Americans still lack access to it

DIEP, the 'gold standard' of breast reconstruction, is under threat

Continuity nursing helped my family in our darkest PICU moments

WuXi out of biotech trade group, U.S. and China relations to blame

hotspot

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

EPA limits use of carcinogenic gas for sterilizing medical devices

The high cost of giving birth even with insurance

Pushing for an NIH office for post

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

EPA limits use of carcinogenic gas for sterilizing medical devices

United colonoscopy coverage change 'may cost lives,' doctors say

First U.S. drug developed to treat liver disease MASH is approved

Heart attack and stroke risk calculators need revising

Walensky prepares to leave CDC — and Congress — behind

explore

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Amid AI frenzy, a top HHS official's quest to create safeguards

Heart attack and stroke risk calculators need revising

Amid AI frenzy, a top HHS official's quest to create safeguards

Medicare coverage of Wegovy, once blocked, now looks possible

EPA limits use of carcinogenic gas for sterilizing medical devices

entertainment

Wikipedia

focus

entertainment